SC Pharmaceuticals(SZ:002693) Sou Hu Cai Jing·2025-08-04 08:04Core Viewpoint - The company is exploring opportunities to leverage the benefits of the Hainan Free Trade Zone (Port) policies to enhance its business in the pharmaceutical and healthcare sectors, including drug research and development, clinical trials, and cross-border medical services [1] Group 1: Company Strategy - The company is a national high-tech enterprise and has maintained an internationalization strategy over the years [1] - It has successfully passed GMP inspections from the US FDA, EU EMA, Philippines FDA, and Saudi Arabia SFDA, covering peptide raw materials and sterile injectables [1] - The company possesses comprehensive capabilities in generic drug research, registration, and patent management [1] Group 2: Business Development - The company has a rich pipeline of research and development projects [1] - To mitigate the risk of delisting, the company's board is actively implementing measures in marketing, peptide business exports, production, and cost control [1]